Cargando…

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies

Detalles Bibliográficos
Autores principales:	Ruprecht, C, Berlinger, L, Trkola, A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767968/ http://dx.doi.org/10.1186/1742-4690-6-S3-P65

Ejemplares similares

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
por: Ruprecht, Claudia R., et al.
Publicado: (2011)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

P04-44. Generation of antibody responses to HIV-1 membrane proximal external region (MPER) antigen
por: Holl, TM, et al.
Publicado: (2009)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Refined identification of neutralization-resistant CRF02_AG viruses and their sensitivity to anti-MPER neutralizing antibodies
por: Jacob, RA, et al.
Publicado: (2012)

P04-02. Increased breadth and potency of the neutralizing antibody response among dually-HIV-1-infected individuals
por: Powell, RL, et al.
Publicado: (2009)

Low levels of anti-MPER antibodies are detectable in viremic HIV infected
por: Carrillo, J, et al.
Publicado: (2012)

P19-50. Simulation of an MPER peptide samples epitope conformations of two broadly neutralizing antibodies
por: Wiehe, K, et al.
Publicado: (2009)

Cross-clade neutralization of HIV-1 by a monoclonal antibody obtained by immunization with liposomes containing lipid A and a synthetic MPER peptide
por: Matyas, GR, et al.
Publicado: (2012)

A comprehensive binding and neutralization analysis of plasma of HIV-1 subtype-C infected donors from India suggest MPER directed neutralization
por: Andrabi, R, et al.
Publicado: (2012)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 determinant for neutralization but not for antigen recognition
por: Weissenhorn, W, et al.
Publicado: (2012)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Affinity maturation pathway of an anti-MPER neutralizing mAb, CAP206-CH12
por: Tumba, NL, et al.
Publicado: (2012)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys
por: Basavapathruni, A, et al.
Publicado: (2009)

OA021-04. HIV-1 gp41 envelope MPER mutation altered epitope conformation in lipid and increased sensitivity to 2F5 and 4E10 neutralizing antibodies
por: Shen, X, et al.
Publicado: (2009)

DNA vaccines that express the MPER of HIV-1 gp41 elicit different antibodies depending upon their transmembrane and cytoplasmic domains
por: Scott, JK, et al.
Publicado: (2012)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

P04-39. Recognizing a dynamic HIV-1 target: a structural look at the interaction between bnAb 2F5 and varying gp41 MPER sequences
por: Julien, J, et al.
Publicado: (2009)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

P04-43. Neutralizing antibody responses against conformational envelope epitopes in early HIV-1 infection
por: Bar, KJ, et al.
Publicado: (2009)

Functional properties of an ensemble of candidate germline-encoded precursors of the anti-MPER antibody 4E10
por: Finton, K, et al.
Publicado: (2012)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from subtype-C HIV-1 infected north Indians; implications for MPER directed HIV-1 neutralization
por: Andrabi, Raiees, et al.
Publicado: (2012)

P05-06. Masking of MPER epitopes through self-associations
por: Strong, RK, et al.
Publicado: (2009)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
por: Jeffs, S, et al.
Publicado: (2009)

Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
por: Krebs, Shelly J., et al.
Publicado: (2014)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8
por: Soto, Cinque, et al.
Publicado: (2016)

An MPER antibody neutralizes HIV-1 using germline features shared among donors
por: Zhang, Lei, et al.
Publicado: (2019)

Correction: Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA
Publicado: (2015)

P04-46. Broadly cross-neutralizing activity in plasma of HIV-1 and HIV-2 infected individuals
por: Fenyö, E, et al.
Publicado: (2009)

P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells
por: Todd, CA, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
por: Pinto, Dora, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_28sscvueh646t458909fjnakr3